Ram Kumar Dhaked
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ram Kumar Dhaked has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Vinita Chauhan Kushwah
Biotechnology Division, Defence Research and Development Establishment, Gwalior, 474002, India
6 shared publicationsAbhinandan Patnaik
5 shared publicationsSurabhi Agnihotri
Biotechnology Division, Defence Research and Development Establishment, Gwalior, 474002, India
5 shared publicationsSharad Kumar Rai
Biotechnology Division, Defence Research and Development Establishment, Gwalior, India
4 shared publicationsDeeksha Disoriya
Biotechnology Division, Defence Research and Development Establishment, Gwalior, India
2 shared publicationsManorama Vimal
Test & Evaluation Division Defence Research and Development Establishment Gwalior MP India
2 shared publications
Latest Publications
- 31 August 2026
- Published by Wolters Kluwer Health in Reviews and Research in Medical Microbiology
Resistome profile of a multidrug-resistant Escherichia coli isolated from an urban river body under high anthropogenic stress
Emergence of antimicrobial resistance (AMR) in freshwater ecosystems like rivers is a growing public health crisis driven by the release of untreated household, hospital and agricultural sewage. These contaminated freshwater sources have become reservoirs for resistant bacteria, facilitating the spread of these pathogens across different environmental zones. The continuous and unchecked influx of drugs, heavy metals and disinfectants from sewage has exerted selective enrichment of resistomes in aquatic pathogens. These resistance genes are shared and spread through plasmids or bacteriophage-derived elements and several metagenomic studies have reported the isolation of bacteria harbouring these resistance determinants in polluted rivers. The implications of such findings on public health are severe, especially on communities which are reliant on river waters for drinking and recreational activities. We were able to isolate and characterize a MDR Escherichia coli strain through whole genome sequencing. Presence of over 50 chromosomal resistance genes with diverse AMR gene families [e.g. major facilitator superfamily (MFS), resistance-nodulation-division (RND) family] and resistance mechanisms along with phage elements from the order Caudovirales , highlighted AMR risks in river reaches within dense human and livestock population. APH(3’) and quinolone resistance protein family genes were found in associated plasmids implying their transfer potential within related bacterial communities. Collectively, the findings of this study constitutes a first-hand report on the presence of a high-risk, broad spectrum resistant pathogen, stressing over the importance of expanding the environmental resistome tracking.
- 31 August 2026
- Published by Wolters Kluwer Health in Reviews and Research in Medical Microbiology
Resistome profile of a multidrug-resistant Escherichia coli isolated from an urban river body under high anthropogenic stress
Emergence of antimicrobial resistance (AMR) in freshwater ecosystems like rivers is a growing public health crisis driven by the release of untreated household, hospital and agricultural sewage. These contaminated freshwater sources have become reservoirs for resistant bacteria, facilitating the spread of these pathogens across different environmental zones. The continuous and unchecked influx of drugs, heavy metals and disinfectants from sewage has exerted selective enrichment of resistomes in aquatic pathogens. These resistance genes are shared and spread through plasmids or bacteriophage-derived elements and several metagenomic studies have reported the isolation of bacteria harbouring these resistance determinants in polluted rivers. The implications of such findings on public health are severe, especially on communities which are reliant on river waters for drinking and recreational activities. We were able to isolate and characterize a MDR Escherichia coli strain through whole genome sequencing. Presence of over 50 chromosomal resistance genes with diverse AMR gene families [e.g. major facilitator superfamily (MFS), resistance-nodulation-division (RND) family] and resistance mechanisms along with phage elements from the order Caudovirales , highlighted AMR risks in river reaches within dense human and livestock population. APH(3’) and quinolone resistance protein family genes were found in associated plasmids implying their transfer potential within related bacterial communities. Collectively, the findings of this study constitutes a first-hand report on the presence of a high-risk, broad spectrum resistant pathogen, stressing over the importance of expanding the environmental resistome tracking.
- 13 May 2026
- Published by Springer Nature in Archives of Toxicology
- Vol. 100 (9) , 4257-4273
Development of novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives for inhibiting the catalytic activity of botulinum neurotoxins type B and F: in silico, in vitro & in vivo evaluation
Botulinum neurotoxins (BoNTs) are the most pernicious toxin and category 'A' bioterrorism agent, responsible for 'botulism', a rare but fatal disease. Toxins are divided into seven toxinotypes from A-G, where A, B, E, and F are accountable for human botulism. The available treatment strategies are inadequate and ineffective for post-neuronal intoxication. We report novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives targetingthe catalytic site of VAMP-acting serotypes (BoNT/B and F). Inhibitory potential of the synthesized compounds was studied using a framework of in silico and experimental approaches. Inhibitory activity and binding affinity were evaluated using substrate-based cleavage and SPR assays. Compound efficacy was tested in mice through pre-mixed, prophylactic, and therapeutic strategies. Molecular dynamics simulations analyzed binding interactions, structural fluctuations, and complex stability. Endopeptidase assay revealed that the selected compounds displayed ≥ 80% inhibition of BoNT/B and F catalytic activity, with IC50 values ranging from 17.58 to 34.05 µM. SPR analysis displayed binding affinity of these molecules ranging from 8.13E-06 to 7.69E-04 for both the proteins. In the mouse bioassay, the selected molecules displayed complete protection and extension in survival of up to 20-fold. MD simulation study supported the experimental finding, revealing key interactions with HExxH and other active site residues forming stable conformation throughout the simulation time. Among them, compounds A15 and A36 were predicted to be more effective inhibitors of BoNT/B and F serotypes, respectively. These findings could lay a promising way for the development of novel therapeutics by reducing disease severity, enhancing survivability, and recovery where no post-exposure therapy presently available.
- 13 May 2026
- Published by Springer Nature in Archives of Toxicology
- Vol. 100 (9) , 4257-4273
Development of novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives for inhibiting the catalytic activity of botulinum neurotoxins type B and F: in silico, in vitro & in vivo evaluation
Botulinum neurotoxins (BoNTs) are the most pernicious toxin and category 'A' bioterrorism agent, responsible for 'botulism', a rare but fatal disease. Toxins are divided into seven toxinotypes from A-G, where A, B, E, and F are accountable for human botulism. The available treatment strategies are inadequate and ineffective for post-neuronal intoxication. We report novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives targetingthe catalytic site of VAMP-acting serotypes (BoNT/B and F). Inhibitory potential of the synthesized compounds was studied using a framework of in silico and experimental approaches. Inhibitory activity and binding affinity were evaluated using substrate-based cleavage and SPR assays. Compound efficacy was tested in mice through pre-mixed, prophylactic, and therapeutic strategies. Molecular dynamics simulations analyzed binding interactions, structural fluctuations, and complex stability. Endopeptidase assay revealed that the selected compounds displayed ≥ 80% inhibition of BoNT/B and F catalytic activity, with IC50 values ranging from 17.58 to 34.05 µM. SPR analysis displayed binding affinity of these molecules ranging from 8.13E-06 to 7.69E-04 for both the proteins. In the mouse bioassay, the selected molecules displayed complete protection and extension in survival of up to 20-fold. MD simulation study supported the experimental finding, revealing key interactions with HExxH and other active site residues forming stable conformation throughout the simulation time. Among them, compounds A15 and A36 were predicted to be more effective inhibitors of BoNT/B and F serotypes, respectively. These findings could lay a promising way for the development of novel therapeutics by reducing disease severity, enhancing survivability, and recovery where no post-exposure therapy presently available.
- 17 January 2026
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1) , 49
Therapeutic potential of [(8-hydroxyquinolin-7-yl)(phenyl)methylamino] benzoic acid regioisomers against human-intoxicating botulinum neurotoxin serotypes: computational modeling to in vivo protection
- 17 January 2026
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1) , 49
Therapeutic potential of [(8-hydroxyquinolin-7-yl)(phenyl)methylamino] benzoic acid regioisomers against human-intoxicating botulinum neurotoxin serotypes: computational modeling to in vivo protection
- 1 August 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (6) , e70148
Targeting the Enzymatic Site of Botulinum Neurotoxin Type E With 8‐Hydroxyquinolinol–Based Inhibitors: In Silico, In Vitro, and In Vivo Evaluation
Botulinum neurotoxins are the most potent toxins responsible for causing flaccid paralysis of muscles by blocking the release of acetylcholine at the neuromuscular junction. There are no postexposure therapeutics and effective active/passive prophylaxis available for the treatment. Therefore, it is highly desirable to develop a potential antidote to counter botulinum neurotoxicity. In this study, ~800 molecules were mined by a structure similarity search from open databases and docked into the pocket of the catalytic domain of botulinum toxin type E using AutoDock 4.2. Twenty‐four small molecules with the best scoring function were selected and evaluated using in vitro and in vivo assays. Among these, two molecules, NSC1011 and NSC1012, were identified as inhibiting the catalytic activity of BoNT/E, with IC50 values of 31.25 ± 1.0 μM and 55.45 ± 5.2 μM and KD of 5.54E−07 and 6.51E−06 M, respectively. To find inhibitors that can reverse the neurotoxicity more effectively, we have derived and synthesized 12 analogs of NSC1011. These compounds showed higher inhibition than the parent molecules, with IC50 and KD values of 4.375 ± 2.3 µM and 1.61E−08 M (C25.12) and 10.25 ± 3.0 µM and 4.70E‐08 M (C25.9). Compounds C25.9 and C25.12 completely protected mice in premixed doses and led to significant extension in survival of up to 60 h with therapeutic treatment. This study showed that these 8‐HQ derivatives had the potency to inhibit BoNT/E by interacting with the active site. Further studies could lead to the development of undiscovered postexposure therapeutics against this deadly neurotoxin.
- 1 August 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (6) , e70148
Targeting the Enzymatic Site of Botulinum Neurotoxin Type E With 8‐Hydroxyquinolinol–Based Inhibitors: In Silico, In Vitro, and In Vivo Evaluation
Botulinum neurotoxins are the most potent toxins responsible for causing flaccid paralysis of muscles by blocking the release of acetylcholine at the neuromuscular junction. There are no postexposure therapeutics and effective active/passive prophylaxis available for the treatment. Therefore, it is highly desirable to develop a potential antidote to counter botulinum neurotoxicity. In this study, ~800 molecules were mined by a structure similarity search from open databases and docked into the pocket of the catalytic domain of botulinum toxin type E using AutoDock 4.2. Twenty‐four small molecules with the best scoring function were selected and evaluated using in vitro and in vivo assays. Among these, two molecules, NSC1011 and NSC1012, were identified as inhibiting the catalytic activity of BoNT/E, with IC50 values of 31.25 ± 1.0 μM and 55.45 ± 5.2 μM and KD of 5.54E−07 and 6.51E−06 M, respectively. To find inhibitors that can reverse the neurotoxicity more effectively, we have derived and synthesized 12 analogs of NSC1011. These compounds showed higher inhibition than the parent molecules, with IC50 and KD values of 4.375 ± 2.3 µM and 1.61E−08 M (C25.12) and 10.25 ± 3.0 µM and 4.70E‐08 M (C25.9). Compounds C25.9 and C25.12 completely protected mice in premixed doses and led to significant extension in survival of up to 60 h with therapeutic treatment. This study showed that these 8‐HQ derivatives had the potency to inhibit BoNT/E by interacting with the active site. Further studies could lead to the development of undiscovered postexposure therapeutics against this deadly neurotoxin.
- 2 April 2025
- Published by Springer Nature in 3 Biotech
- Vol. 15 (5) , 108
Analytical techniques and molecular platforms for detection and surveillance of antimicrobial resistance: advancements of the past decade
Developing countries have been able to control and minimise the mortality rates caused by pathogenic infections by ensuring affordable access to antibiotics. However, a large number of bacterial ailments are treated with wrong antibiotic prescription due to improper disease diagnosis. Apart from healthcare, antibiotics are also imprudently utilised in crop processing and animal husbandry. This unsupervised usage of antibiotics has propelled the generation of multidrug-resistant species of bacteria. Presently, several traditional antimicrobial susceptibility/resistance tests (AST/ART) are available; however, the accuracy and reproducibility of these tests are often debatable. Rigorous efforts are essential to develop techniques and methods which substantially decrease turnaround time for resistance screening. The present review has comprehensively incorporated the improvements in instrumentation and molecular methods for antimicrobial resistance studies. We have enlisted some innovative takes on conventional techniques such as isothermal calorimetry, Raman spectroscopy, mass spectrometry and microscopy. The contributions of modern molecular tools such as CRISPR–Cas, aptamers and Oxford-MinION sequencers have also been discussed. Persistent evolution has been observed towards adding innovation in diagnostic platforms for drug resistome screening, with the major attraction being the involvement of non-conventional analytical methods and technological improvements in existing setups. This review highlights these updates and provides a detailed account of principal developments in molecular methods for the testing of drug resistance in bacteria.
- 2 April 2025
- Published by Springer Nature in 3 Biotech
- Vol. 15 (5) , 108
Analytical techniques and molecular platforms for detection and surveillance of antimicrobial resistance: advancements of the past decade
Developing countries have been able to control and minimise the mortality rates caused by pathogenic infections by ensuring affordable access to antibiotics. However, a large number of bacterial ailments are treated with wrong antibiotic prescription due to improper disease diagnosis. Apart from healthcare, antibiotics are also imprudently utilised in crop processing and animal husbandry. This unsupervised usage of antibiotics has propelled the generation of multidrug-resistant species of bacteria. Presently, several traditional antimicrobial susceptibility/resistance tests (AST/ART) are available; however, the accuracy and reproducibility of these tests are often debatable. Rigorous efforts are essential to develop techniques and methods which substantially decrease turnaround time for resistance screening. The present review has comprehensively incorporated the improvements in instrumentation and molecular methods for antimicrobial resistance studies. We have enlisted some innovative takes on conventional techniques such as isothermal calorimetry, Raman spectroscopy, mass spectrometry and microscopy. The contributions of modern molecular tools such as CRISPR–Cas, aptamers and Oxford-MinION sequencers have also been discussed. Persistent evolution has been observed towards adding innovation in diagnostic platforms for drug resistome screening, with the major attraction being the involvement of non-conventional analytical methods and technological improvements in existing setups. This review highlights these updates and provides a detailed account of principal developments in molecular methods for the testing of drug resistance in bacteria.
- 3 August 2024
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 33 (9) , 1625-1642
Novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid analogs targeting the active site of botulinum neurotoxins: designing, synthesis, and biological evaluation
- 3 August 2024
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 33 (9) , 1625-1642
Novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid analogs targeting the active site of botulinum neurotoxins: designing, synthesis, and biological evaluation
- Open Access
- 28 May 2024
- Published by Innovation Forever Publishing Group Limited in Journal of Modern Biology and Drug Discovery
- Vol. 3
Fluorescence Thermal Shift Assay based High Through-put Screening in Small Molecule Drug Discovery: A Brief Overview
Background: The Early drug discovery process was majorly phenotypic, lacking target specificity, and mechanism of action causing short and/or long-term toxicological impacts on the patients leading to several drug withdrawals from the market. Biochemical procedures and methods used in drug discovery and development make it lengthy in terms of time requiring approx. 15 years with the investment of billions of dollars for a new drug molecule. Technological advancement leading to the identification of protein structures through crystallography paved a new path toward targeted drug discovery. Objective: This paper provides a brief overview of the use of the fluorescence thermal shift assay (FTSA) as a high throughput (HTS) screening technique in small molecule drug discovery. Methods: The article discusses the principles of thermal denaturation techniques and how they are applied in drug discovery. It highlights the advantages of FTSA over other biophysical methods, including its label-free, cost-effective, and high HTS nature. The review also presents a comparative analysis of FTSA with techniques such as isothermal titration calorimetry (ITC), mass spectrometry (MS), nuclear magnetic resonance (NMR), surface plasmon resonance (SPR), X-ray crystallography(X-RD), circular dichroism (CD), and differential scanning calorimetry (DSC). Results: The FTSA technique is described as a powerful tool that addresses the limitations of larger protein requirements, specific assay development, and low HTS associated with other thermal denaturation methods. Unlike biochemical and cellular assays that measure secondary effects, FTSA directly estimates the binding of small molecules to target proteins. Conclusion: The review concludes that FTSA is the only biophysical method that satisfies the three key prerequisites of being label-free, cost-effective, and suitable for high HTS screening in small molecule drug discovery.
- 28 May 2024
- Published by Innovation Forever Publishing Group Limited in Journal of Modern Biology and Drug Discovery
- Vol. 3
Open AccessFluorescence Thermal Shift Assay based High Through-put Screening in Small Molecule Drug Discovery: A Brief Overview
Background: The Early drug discovery process was majorly phenotypic, lacking target specificity, and mechanism of action causing short and/or long-term toxicological impacts on the patients leading to several drug withdrawals from the market. Biochemical procedures and methods used in drug discovery and development make it lengthy in terms of time requiring approx. 15 years with the investment of billions of dollars for a new drug molecule. Technological advancement leading to the identification of protein structures through crystallography paved a new path toward targeted drug discovery. Objective: This paper provides a brief overview of the use of the fluorescence thermal shift assay (FTSA) as a high throughput (HTS) screening technique in small molecule drug discovery. Methods: The article discusses the principles of thermal denaturation techniques and how they are applied in drug discovery. It highlights the advantages of FTSA over other biophysical methods, including its label-free, cost-effective, and high HTS nature. The review also presents a comparative analysis of FTSA with techniques such as isothermal titration calorimetry (ITC), mass spectrometry (MS), nuclear magnetic resonance (NMR), surface plasmon resonance (SPR), X-ray crystallography(X-RD), circular dichroism (CD), and differential scanning calorimetry (DSC). Results: The FTSA technique is described as a powerful tool that addresses the limitations of larger protein requirements, specific assay development, and low HTS associated with other thermal denaturation methods. Unlike biochemical and cellular assays that measure secondary effects, FTSA directly estimates the binding of small molecules to target proteins. Conclusion: The review concludes that FTSA is the only biophysical method that satisfies the three key prerequisites of being label-free, cost-effective, and suitable for high HTS screening in small molecule drug discovery.
- 18 February 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 263 (Pt 1) , 130216
CRISPR-Cas12a assisted recombinase based strand invading isothermal amplification platform designed for targeted detection of Bacillus anthracis Sterne
- 18 February 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 263 (Pt 1) , 130216
CRISPR-Cas12a assisted recombinase based strand invading isothermal amplification platform designed for targeted detection of Bacillus anthracis Sterne